Companies › LIMN

LIMINATUS PHARMA INC. (LIMN)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001971387 · EDGAR filings · Updated 2026-07-24

LIMINATUS PHARMA INC. (LIMN) has reported institutional ownership of 3.5%, with 15 institutional managers holding positions valued at $253.8K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (2)

• 2026-07-24 — Current report (8-K) filed
• 2026-07-22 — SCHEDULE 13G filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-14 — Insider transaction reported (Form 4)
• 2026-07-14 — SCHEDULE 13D/A filed
• 2026-07-13 — Proxy statement (DEF 14A) filed
• 2026-07-06 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, LIMINATUS PHARMA INC. has 15 institutional holders and institutional ownership of 3.5%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 4 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

Tenon Medical Inc (TNON) · TransCode Therapeutics Inc (RNAZ) · ENSYSCE BIOSCIENCES INC (ENSC) · CYCLERION THERAPEUTICS INC COM (CYCN) · Aptevo Therapeutics Inc (APVO) · BIOMERICA INC (BMRA)